METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY
Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.
1 . A method for treating a subject suffering from a compromised endogenous hematopoietic system, comprising administering to the subject a therapeutically effective amount of adherent stromal cells for inducing repopulation of endogenous hematopoietic cells in the endogenous hematopoietic system.
2 . The method of claim 1 , wherein the endogenous hematopoietic cells were produced by the subject's hematopoietic system.
3 . The method of claim 1 , wherein repopulation of endogenous hematopoietic cells comprises increasing the number of hematopoietic cells in the endogenous hematopoietic system of the subject.
4 . The method of claim 3 , wherein repopulation of endogenous hematopoietic cells comprises increasing the number of hematopoietic cells expressing the CD45+ marker.
5 . The method of claim 1 , wherein the subject has been exposed to radiation.
6 . The method of claim 1 , wherein the subject is immune deficient due to chemotherapy.
7 . The method of claim 1 , wherein the origin of the adherent stromal cells is placenta or adipose tissue.
8 . The method of claim 1 or 7 , wherein the adherent stromal cells were cultured under three dimensional culturing conditions supporting cell expansion.
9 . The method of claim 8 , wherein the cultured adherent stromal cells secrete Flt-3 ligand, IL-6, and SCF into the culture medium.
10 . The method of claim 1 , wherein the origin of the adherent stromal cells is placenta or adipose tissue, and the adherent stromal cells were cultured under three dimensional culturing conditions supporting cell expansion.
11 . The method of claim 1 wherein the subject has been treated with chemotherapy.
12 . A pharmaceutical composition comprising a therapeutically effective amount of adherent stromal cells for inducing repopulation of endogenous hematopoietic cells in the endogenous hematopoietic system in a subject suffering from a compromised hematopoietic system.
13 . The pharmaceutical composition of claim 12 , wherein the endogenous hematopoietic cells were produced by the subject's hematopoietic system.
14 . The pharmaceutical composition of claim 12 , wherein repopulation of endogenous hematopoietic cells in the endogenous hematopoietic system comprises increasing the number of endogenous hematopoietic cells in the hematopoietic system of the subject.
15 . The pharmaceutical composition of claim 12 , wherein repopulation of hematopoietic cells in the endogenous hematopoietic system comprises increasing the number of hematopoietic cells expressing the CD45+ marker.
16 . The pharmaceutical composition of claim 12 , wherein the subject has been exposed to radiation.
17 . The pharmaceutical composition of claim 12 , wherein the subject is immune deficient due to chemotherapy.
18 . The pharmaceutical composition of claim 12 , wherein the origin of the adherent stromal cells is placenta or adipose tissue.
19 . The pharmaceutical composition of claim 12 or 18 , wherein the adherent stromal cells were cultured under three dimensional culturing conditions supporting cell expansion.
20 . The pharmaceutical composition of claim 19 , wherein the cultured adherent stromal cells secrete Flt-3 ligand, IL-6, and SCF into the culture medium.
21 . The pharmaceutical composition of claim 12 , wherein the origin of the adherent stromal cells is placenta or adipose tissue, and the adherent stromal cells were cultured under three dimensional culturing conditions supporting cell expansion.
22 . The pharmaceutical composition of claim 12 wherein the subject has been treated with chemotherapy.